Patrys has today announced that its wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a $2.7 million refund for the 2022/2023 financial year under the Federal Government’s R&D Tax Incentive scheme.
Patrys has today announced that its wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a $2.7 million refund for the 2022/2023 financial year under the Federal Government’s R&D Tax Incentive scheme.